Generics - Anti-Arthritics/Rheumatics, Biotechnology

Filter

Popular Filters

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Baxter and Coherus in up to $246 million deal for biosimilar etanercept

04-09-2013

US companies Baxter International (NYSE:BAX) and Coherus Biosciences have entered into an exclusive collaboration…

AmgenAnti-Arthritics/RheumaticsBaxter InternationalBiotechnologyCoherus BioSciencesEnbreletanerceptGenericsLicensingResearch

Phase III data support biosimilarity of BOW-015 to Remicade

29-08-2013

Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

EMA's CHMP backs approval of first two monoclonal antibody biosimilars of blockbuster Remicade

29-06-2013

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRegulationRemsima

Sandoz initiates Ph III trial for biosimilar Enbrel

24-06-2013

Swiss drug major Novartis' (NOVN: VX) generics unit Sandoz has initiated a major Phase III clinical trial…

AmgenAnti-Arthritics/RheumaticsBiotechnologyDermatologicalsEnbrelGenericsNovartisResearchSandoz

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

17-04-2013

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

Biosimilars threaten to burst Humira's blockbuster bubble

29-11-2012

US health care major Abbott Laboratories' (NYSE: ABT) Humira (adalimumab) has a strong reputation as…

Abbott LaboratoriesAnti-Arthritics/RheumaticsBiotechnologyGenericsHumiraMarkets & Marketing

AET BioTech and BioXpress to co-develop biosimilar Humira

02-11-2012

Plans to develop another biosimilar version of Abbott Laboratories blockbuster rheumatoid arthritis drug…

Abbott LaboratoriesadalimumabAET BioTechAnti-Arthritics/RheumaticsBiotechnologyBioXpress TherapeuticsGenericsHumiraProductionResearch

Kyowa Hakko sets up biosimilars joint venture with Fujifilm

29-03-2012

Japanese digital camera and medical equipment conglomerate Fujifilm and drugmaker Kyowa Hakko Kirin have…

Anti-Arthritics/RheumaticsAsia-PacificBiotechnologyFujifilm Kyowa Kirin BiologicsGenericsHumiraKyowa Hakko KirinMergers & AcquisitionsResearch

Back to top